Loading
A phase 3 trial of Sacituzumab tirumotecan, Pembrolizumab, Pemetrexed in non-small-cell lung cancer and small-cell lung cancer, run by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., active and no longer recruiting.
A Study of SKB264 in Combination With Pembrolizumab Versus Chemotherapy in Combination With Pembrolizumab as First-Line Treatment for PD-L1 Negative Patients With Locally Advanced or Metastatic Non-Squamous Non-Small Cell Lung Cancer is a phase 3 interventional study registered as NCT06711900 by Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd., with 432 participants planned, started 2024-10-30 and due to reach its primary completion in 2026-12. Interventions recorded: SKB264, Pembrolizumab, pemetrexed, carboplatin or cisplatin. Conditions listed: Non-Small Cell Lung Cancer. No results are recorded here; the registry entry is the source.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Pembrolizumab.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Pembrolizumab.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Sichuan Kelun-Biotech, Sacituzumab tirumotecan, Small-cell lung cancer, Non-small-cell lung cancer.
Shares Pemetrexed, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.
Shares Sacituzumab tirumotecan, Pemetrexed, Small-cell lung cancer, Pembrolizumab.
Shares Sacituzumab tirumotecan, Small-cell lung cancer, Pembrolizumab, Immune checkpoint inhibitors.